Medical/Pharmaceuticals

Akeso Secures $250 Million USD to Propel Global Expansion of Its Innovative Drug Pipeline

Expediting International Clinical Trials for Pivotal Products Key Participants Include International Long-Term and Healthcare Funds HONG KONG, Oct. 13, 2024 /PRNewswire/ -- Akeso Biopharma (9926. HK) ("Akeso", the "Company" ) announced that it has successfully raised approximately$250 million US...

2024-10-13 20:27 4575

Sunvozertinib Granted Breakthrough Therapy Designation by China CDE for the First-Line Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Fourth Breakthrough Therapy Designation for sunvozertinib in NSCLC with EGFR exon20ins SHANGHAI, Oct. 13, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the Center...

2024-10-13 16:04 3274

Ailux Biologics, a Division of XtalPi, Enters into a License Agreement with Janssen Biotech on Biologics AI Platform

CAMBRIDGE, Mass., Oct. 12, 2024 /PRNewswire/ -- XtalPi, a global leader in AI drug discovery, announced today a license agreement between Ailux Biologics, a division of XtalPi Inc., and Janssen Biotech, Inc.,(Janssen) a Johnson & Johnson company, on one of its proprietary biologics AI platforms. ...

2024-10-12 16:57 5379

Baird Medical Announces Preliminary Financial Results for the Six Months Ended June 30, 2024

Total revenues increased to US$13.1 million, representing 13.8% year-over-year growth Net income reached US$4.4 million, representing 85.8% year-over-year growth GUANGZHOU, China, Oct. 11, 2024 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"...

2024-10-11 20:00 5484

Delegation of International Communication Experts and Foreign Media Outlets Visits Emerging Industry Enterprises in Zhongshan, Guangdong Province

BEIJING, Oct. 10, 2024 /PRNewswire/ -- On October 9, 2024, the delegation of international communication experts and foreign media outlets, themed "The World Comes to Zhongshan" and organized by the CICG Academy of Translation and Interpretation, visited several representative enterprises in Zhon...

2024-10-11 00:53 2836

Datasea Pre-announces Estimated First Quarter 2025 Fiscal Year Revenue of approximately $22.7 Million, Up 230% Year-Over-Year

BEIJING, Oct. 10, 2024 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), aNevada-registered digital technology company focused on innovations in acoustics high-tech and 5G AI multimodal digital technologies, today pre-announced that its revenue for the first quarter of fis...

2024-10-10 21:45 4419

111 Inc. Expands National Supply Chain Network with New Fulfillment Centers across South and Central China

SHANGHAI, Oct. 10, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, today announced that new fulfillme...

2024-10-10 18:02 4380

Harbour BioMed Announces Publication of the Phase I Study Results for Porustobart in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Oct. 9, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunolo...

2024-10-10 11:04 2351

Arbele Announces Strategic Collaborations on AI Precision Oncology and Manufacturing to Advance CDH17-Targeted Immunotherapeutics

SEATTLE, Oct. 9, 2024 /PRNewswire/ -- Arbele, a leading innovator in biopharmaceutical & biotechnology focused on targeting cadherin-17 (CDH17), is pleased to announce strategic collaborations in precision oncology using artificial intelligence (AI) to advance targeted immunotherapeutics of bisp...

2024-10-09 23:00 2210

Baird Medical Lists in the U.S. on the Nasdaq Exchange

Company Rings Opening Bell to Celebrate Closure of Business Combination and Begins Journey as a Public Company; Shares trade under "BDMD" Ticker FORT MILL, S.C., Oct. 9, 2024 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leading micro...

2024-10-09 20:30 2346

Nona Biosciences Enters Strategic Collaboration with OverT Bio to Advance Next-Generation Cell Therapies for Solid Tumors

CAMBRIDGE, Mass., Oct. 9, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), today announced a strategic collaboration with OverT Bio, aNew York-based biotechnology company. The collaboration will focus on developing ne...

2024-10-09 20:00 2070

Alpha Fusion Accelerates Astatine-based Drug Discovery with Series B Funding

OSAKA, Japan, Oct. 9, 2024 /PRNewswire/ -- Alpha Fusion, Inc. (CEO: Sunao Fujioka, headquartered in Kita-ku, Osaka), has raised a total of ¥1.02 billion through a Series B funding round. The round was led by SBI Investment Co., Ltd. andOSAKA University Venture Capital, with participation from sev...

2024-10-09 15:23 2176

Joint Venture Company Established for Incubation of Early Drug Discovery Programs; Investment from Takeda, Astellas and Sumitomo Mitsui Banking

TOKYO, Oct. 8, 2024 /PRNewswire/ -- Ciconia Bioventures Inc. (Representative Director, Founder CEO:Toshio Fujimoto, "Ciconia") today announced its establishment as a joint venture company based on a master agreement signed on April 22, 2024 by Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:...

2024-10-09 10:00 2084

Rege Nephro Co., Ltd. Successfully Completes Series B Funding to Accelerate Kidney Disease Therapy Trials

KYOTO, Japan, Oct. 7, 2024 /PRNewswire/ -- Rege Nephro Co., Ltd. ( https://www.regenephro.co.jp/ ) is excited to  announcethat the company has successfully developed a funding plan of total approximately17 million dollar (2.5 billion JPY) in new Series B funding and ...

2024-10-09 07:39 3937

Baird Medical to Participate in Roth's 3rd Annual Healthcare Opportunities Conference

GUANGZHOU, China, Oct. 8, 2024 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China which has recently expanded into the U.S. market following its receipt of US...

2024-10-09 04:30 2162

Korea's SK bioscience Acquires Stake in U.S. Biotech Fina Biosolutions

* SK bioscience invested USD 3 million in FinaBio, a U.S. company specializing in next-generation conjugate vaccine technology. * With the agreement, SK bioscience expects to improve the immunogenicity and productivity of conjugate vaccines, including those for pneumoniae and typhoid. * The ...

2024-10-08 20:00 2634

MicuRx Pharmaceuticals Announces Promising Results from MRX-5 Study for Treating Mycobacterium abscessus Infections

FOSTER CITY, Calif., Oct. 8, 2024 /PRNewswire/ -- MicuRx Pharmaceuticals is excited to announce the publication of groundbreaking research on MRX-5, a novel oral oxaborole prodrug, demonstrating significant potential in the treatment of pulmonary infections caused byMycobacterium abscessus (Mab),...

2024-10-08 13:38 1956

Sciwind Biosciences Announces Oral Presentation on Oral GLP-2 Research Progress at the 32nd United European Gastroenterology Week (UEG Week 2024)

BEIJING and HANGZHOU, China, Oct. 7, 2024 /PRNewswire/ -- The 32nd United European Gastroenterology Week (UEG Week 2024) will take place inVienna, Austria , fromOctober 12 to 15, 2024. UEG Week is the largest gastroenterology conference inEurope and one of the leading meetings worldwide. It brings...

2024-10-08 10:00 2155

MediLink Announces Global Clinical Trial Collaboration and Supply Agreement on YL201 Combination Therapy

SUZHOU, China, Oct. 7, 2024 /PRNewswire/ -- MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink"), a clinical-stage biotech company, today announced a global clinical trial collaboration and supply agreement with Amgen Inc. Amgen will lead a global clinical study to evaluate the therapeutic poten...

2024-10-08 08:00 2254

HoneyNaps actively supplies "AI solutions" to U.S. medical institutions

* Rapid commercialization and delivery to the U.S. after FDA approval * Aiming to achieve a 10% market share within three years * Aggressive sales and expansion of distribution network through U.S. subsidiaries BOSTON, Oct. 7, 2024 /PRNewswire/ -- HoneyNaps announced on September 9th that it...

2024-10-07 21:00 1731
1 ... 82838485868788 ... 254